Immutep and Dr. Reddy's Sign Strategic Collaboration Agreement
Immutep (IMMP) and Dr. Reddy's Laboratories (RDY) announced that their respective wholly-owned subsidiaries, Immutep SAS and Dr. Reddy's Laboratories SA, have entered into a strategic collaboration and exclusive licensing agreement for the development and commercialisation of Eftilagimod Alfa in all countries outside North America, Europe, Japan, and Greater China. The terms of the licensing agreement provide Immutep with significant milestones and preserves its ability to capture material future upside in the licensed markets as efti advances commercially. Further, Immutep holds the global manufacturing rights to the product across all markets and will supply the product to Dr. Reddy's in the licensed markets, while Immutep retains all rights to the product in the key pharmaceutical markets, including North America, Europe, and Japan. Additionally, as per the agreement, Immutep will receive from Dr. Reddy's an upfront payment of USD 20 million. It is also eligible to receive potential regulatory development and commercial milestone payments of up to USD 349.5 million, plus double-digit royalties on commercial sales in these markets.
Discover Tomorrow's Bullish Stocks Today
Analyst Views on IMMP
No data
About IMMP
About the author
Immutep's First LAG-3 Antibody Trial Shows Positive Phase I Results
- Clinical Trial Progress: Immutep's IMP761 has completed the 2.5 and 7 mg/kg dosing levels in a Phase I trial with healthy participants, demonstrating positive safety and efficacy data without serious adverse reactions, indicating its potential in treating autoimmune diseases.
- Immunosuppressive Effects: The drug exhibited dose-dependent immunosuppressive effects, achieving significant and long-lasting inhibition of T-cell-mediated intradermal reactions to a strong foreign antigen on days 2, 9, and 23, potentially offering new treatment avenues for conditions like rheumatoid arthritis.
- Market Opportunity: As a therapeutic target for autoimmune diseases, LAG-3 positions IMP761 to address large markets, including Type 1 diabetes and multiple sclerosis, which could translate into multi-billion dollar opportunities for the company.
- Future Outlook: Immutep plans to continue the trial as scheduled, with additional updates expected in the first half of 2026, further enhancing market interest and investor confidence in this promising program.
ASX Penny Stocks Highlight: DUG Technology Featured Among Three Key Selections
Market Overview: Australian shares are facing challenges due to global tech sector declines, prompting investors to consider penny stocks, which may offer surprising value and stability despite their smaller size.
DUG Technology Ltd: This technology company, with a market cap of A$281.66 million, has shown improvement in financial health, reducing losses significantly over the past five years, and has potential for future growth despite current profitability challenges.
Immutep Limited: A biotechnology firm focused on immunotherapies, Immutep has a market cap of A$552.65 million and is well-positioned financially, with a strong cash position supporting ongoing clinical trials, despite being pre-revenue.
Wagners Holding Company: With a market cap of A$719.01 million, Wagners has demonstrated robust financial health and significant earnings growth, supported by its inclusion in the S&P/ASX Emerging Companies Index, although it faces challenges with long-term liabilities.
